Articles tagged "Biopsy"

2022 American Transplant Congress
Histologic Borderline Reflects Molecular Injury Not Rejection: Results from the Trifecta Study
P. F. Halloran¹, K. S. Madill-Thomsen¹, Z. Demko², A. Prewett², P. Billings², P. Gauthier², .. and the Trifecta Investigators³
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²Natera Inc., San Carlos, CA, ³., ., AB, Canada
*Purpose: In the Trifecta study (NCT04239703), we recently compared indication biopsy diagnoses (MMDx and histology) and plasma %dd-cfDNA levels for indication biopsies (JASN in press…
2022 American Transplant Congress
Reassessment of Previous Kidney Discards from a Single Large Organ Procurement Organization
S. Bunnapradist¹, T. Seto², A. Cohen², T. Rosenthal¹, G. Danovitch¹
¹David Geffen School of Medicine, Los Angeles, CA, ²One Legacy, Los Angeles, CA
*Purpose: After deceased donor kidneys are recovered, they are offered according to UNOS policy and are discarded if no centers in the country would use…
2022 American Transplant Congress
The Relative Association of Clinical Variables and Histologic Lesions with Molecular Rejection in Kidney Transplant Biopsies
M. L. Sikosana¹, J. Reeve², P. F. Halloran², INTERCOMEX Investigators³
¹University of Alberta, Edmonton, AB, Canada, ²Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ³INTERCOMEX, Edmonton, AB, Canada
*Purpose: Availability of molecular assessment (MMDx) independent of conventional variables (time, clinical, histologic, and HLA antibody) presents an opportunity to re-assess the relative strength of…
2022 American Transplant Congress
The Ontario Anatomic Kidney Score (OAKS) : Quantitative Macroscopic Assessment versus Histological Grading in Pre-transplant Evaluation of Donor Kidneys
J. Mello Offerni¹, D. Matty², H. Abed³, P. Roshanov⁴, A. Sener¹, P. Luke¹
¹Urology, Western University, London, ON, Canada, ²Undergraduate Medical Education, Western University, Schulich School of Medicine & Dentistry, London, ON, Canada, ³Division of Urology, Department of Surgery, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada, ⁴Division of Nephrology, Department of Internal Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada
*Purpose: Quantitative gross assessment of a kidney has not been used to influence the evaluation to utilize a kidney for transplantation. The Ontario Anatomic Kidney…
2022 American Transplant Congress
Treading the Paradigm Shift: A Single Center Comparative Study of Outcomes Between Pre-Emptive and Early Kidney Transplant with Non Pre-Emptive Kidney Transplant Recipients Innational Kidney and Transplant Institute
E. U. Go, L. Baloloy
Organ Transplantation and Vascular Surgery, National Kidney and Transplant Institute, Quezon City, Philippines
*Purpose: To compare the 3-year outcome of pre-emptive and early kidney transplant recipients versus non pre-emptive recipients in our institution from January 2013 to December…
2021 American Transplant Congress
Sampling Renal Biopsies in Pre-Clinical Research for Comprehensive Assessment
C. M. Edwards¹, C. Albert², D. Stern¹, J. Langford¹, W. Day², J. R. DiRito¹, W. M. Saltzman², M. Kashgarian³, J. S. Pober⁴, G. T. Tietjen¹
¹Surgery, Yale School of Medicine, New Haven, CT, ²Biomedical Engineering, Yale School of Medicine, New Haven, CT, ³Pathology, Yale School of Medicine, New Haven, CT, ⁴Immunobiology, Yale School of Medicine, New Haven, CT
*Purpose: Previous literature has demonstrated that single biopsies are not representative of a whole kidney in clinical assessments. In this study we aimed to design…
2021 American Transplant Congress
Detection of Rejection in Kidney Transplant Patients Using an Algorithm That Combines Donor Fraction and Absolute Donor-derived Cell-free DNA
S. Bunnapradist¹, E. Ahmed², M. Maninder², Z. P. Demko², P. R. Billings², H. Tabriziani², P. Gauthier³
¹David Geffen Sch of Med @ UCLA, Los Angeles, CA, ²Natera, Inc., San Carlos, CA, ³Natera, Inc., Los Angeles, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) in the plasma of renal allograft patients is a clinically validated biomarker for allograft injury and rejection. Several dd-cfDNA assays…
2021 American Transplant Congress
Donor-derived Cell-free DNA in Upper Extremity Vascular Composite Allograft Recipients
R. Kalsi¹, M. Abuzeineh², J. Littleton¹, J. T. Shores¹, D. S. Cooney¹, C. Cooney¹, R. J. Redett¹, G. Brandacher¹, D. C. Brennan²
¹Plastic and Reconstructive Surgery, Johns Hopkins University, Baltimore, MD, ²Nephrology, Johns Hopkins University, Baltimore, MD
*Purpose: Diagnosing rejection in VCA recipients relies on clinical exam and biopsy which are both easily confounded by common causes of skin irritation. dd-cfDNA in…
2021 American Transplant Congress
PLA2R Status and Antibody Mediated Rejection in Kidney Transplant with Membranous Nephropathy
H. S. Han¹, A. Urisman², J. Shoji¹
¹Kidney Transplant Service, University of California, San Francisco, San Francisco, CA, ²Pathology, University of California, San Francisco, San Francisco, CA
*Purpose: Membranous nephropathy (MN) in transplanted kidney is categorized as de novo or recurrent disease. This immune complex glomerulopathy presents with varying levels of proteinuria,…
2021 American Transplant Congress
Gene Expression Profiles Assessed by the Nanostring nCounter® Platform May Differentiate Different Types of Rejection, and Importantly, T-Cell Mediated Rejection from BK Virus Nephropathy
K. R. Degner¹, K. J. Swanson¹, S. Parajuli¹, D. Mandelbrot¹, N. Garg¹, F. Aziz¹, M. Mohamed¹, W. Zhong¹, L. Ptak¹, N. A. Wilson¹, R. Woodward², A. Djamali¹
¹University of Wisconsin, Madison, WI, ²CareDx, Inc., San Francisco, CA
*Purpose: Allograft biopsies are considered the gold standard for diagnosis and therapeutic guidance in kidney transplant recipients. Expanding current biopsy assessments to include gene expression…

« Previous Page
1
…
5
6
7
8
9
…
43
Next Page »